CD274 and non-small cell lung carcinoma: Our research findings indicate that 46.3% of NSCLC patients with ROS1 rearrangements exhibit PD-L1 positivity, with 13.4% displaying high levels of PD-L1 expression and 32.9% showing lower levels.